In a new study, researchers identified the most common characteristics of 85 COVID-19 patients who died in Wuhan, China in the early stages of the coronavirus pandemic. The study reports on commonalities of the largest group of coronavirus patient deaths to be studied to date. The paper was published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine.
In “Clinical Features of 85 Fatal Cases of COVID-19 From Wuhan: A Retrospective Observational Study,” researchers from China and the United States report on an analysis of the electronic health records of patients with COVID-19 who died despite treatment at two hospitals in Wuhan: Hanan Hospital and Wuhan Union Hospital between Jan. 9 and Feb. 15, 2020. Wuhan, in China’s Hubei Province, was the epicenter of the COVID-19 outbreak.
“The greatest number of deaths in our cohort were in males over 50 with non-communicable chronic diseases,” stated the authors. “We hope that this study conveys the seriousness of COVID-19 and emphasizes the risk groups of males over 50 with chronic comorbid conditions including hypertension (high blood pressure), coronary heart disease and diabetes.”
The researchers examined the medical records of 85 patients who had died, and recorded information on their medical histories, exposures to coronavirus, additional chronic diseases they had (comorbidities), symptoms, laboratory findings, CT scan results and clinical management. Statistical analyses were then done.
The median age of these patients was 65.8, and 72.9 percent were men. Their most common symptoms were fever, shortness of breath (dyspnea) and fatigue.
Hypertension, diabetes and coronary heart disease were the most common comorbidities. A little over 80 0 percent of patients had very low counts of eosinophils (cells that are reduced in severe respiratory infections) on admission. Complications included respiratory failure, shock, acute respiratory distress syndrome (ARDS) and cardiac arrhythmia, among others. Most patients received antibiotics, antivirals and glucocorticoids (types of steroids). Some were given intravenous immunoglobulin or interferon alpha-2b.
The researchers noted: “The effectiveness of medications such as antivirals or immunosuppressive agents against COVID-19 is not completely known. Perhaps our most significant observation is that while respiratory symptoms may not develop until a week after presentation, once they do there can be a rapid decline, as indicated by the short duration between time of admission and death (6.35 days on average) in our study.”
Based on their findings, eosinophilopenia – abnormally low levels of eosinophils in the blood – may indicate a poor prognosis. The scientists also noted that the early onset of shortness of breath may be used as an observational symptom for COVID-19 symptoms. In addition, they noted that a combination of antimicrobial drugs (antivirals, antibiotics) did not significantly help these patients. The majority of patients studied died from multiple organ failure.
“Our study, which investigated patients from Wuhan, China who died in the early phases of this pandemic, identified certain characteristics. As the disease has spread to other regions, the observations from these areas may be the same, or different. Genetics may play a role in the response to the infection, and the course of the pandemic may change as the virus mutates as well. Since this is a new pandemic that is constantly shifting, we think the medical community needs to keep an open mind as more and more studies are conducted.”
- Measles outbreak in Mexico City
- Spain reports 7000 COVID-19 cases in past 24 hours
- New York COVID-19 cases top 100K, Javits Center used for COVID-19 patients only
- University of Nebraska develops a COVID-19 screening mobile app
- Florida COVID-19: Cases top 10,000, StrongerThanC-19 website
- Polio: Five additional WPV1 cases reported in Pakistan and Afghanistan
- Wearing surgical masks in public could help slow COVID-19 pandemic’s advance: Study
3 thoughts on “New study identifies characteristics of patients with fatal COVID-19”
This is very interesting research/results and really brings me back to president Trump & the CDCs response in regards to treating SARS-COVID-2 with ZPAC antibiotics as 1 of the 2 treatment meds. I honestly cannot take their reccomendations seriously due to their lack of normality, transparency, supportive data, & good ole empathatic sincerety. Furthermore, I believe antibiotics are over-prescribed & should be used only when there is possible loss of life or limb(s). However, I feel this particular study you’ve provided has more of those things mentioned above than all the info provided thus far from the government, (WHO) World Health Organization, the (CDC) Centers for Disease Control, and CDCs linked lab supposedly heading SARS-COV-2 testing, called APHL (www.APHL.org).
If I was being treated for COVID-19 and hear my doctors saying the symptoms are getting worse, that would be the point I would seriously ask them if they’ve done an honest effort to research the evidence of those who are seeing success in the treatments of COVID-19 with Hydrocloraquine and Zpac? Knowing the information has been on the internet with medical professionals, i.e., doctors, MDs, saying they have had success and are saving lives, if my physician told me that he couldn’t treat me because of a lack of studies, I would have to seek help elsewhere due to the doctor suffering from CSTFFTT (Can’t see the forest for the trees) syndrome.
My God, if a person is dying, the stench of politics (“I honestly cannot take their recommendations seriously due to their lack of normality, transparency, supportive data, & good ole empathatic sincerity”) mentality is a big part of the problem humanity is facing.
There are doctors out there trying to talk this disease to death while others are actually doing something about it. We need more of those liberated, intelligent, thoughtful, kind and considerate physicians who take their creed seriously enough to take the extra steps to try.
Exactly ..same with ivermectin..made by merck..but beings it is cheap they wont give out ..proven to be save and save 87% from death.. but ..now they made a new INVESTIGATIONAL pill not approved ,never used before and want to get approved for experimental emergency use..kinda like the deadly vaxx..
If people were the concern and not money (fauci and gates , others ) then ivermectin would be used ..alls they can do is threaten those doctors nurses hospitals and pharma from giving it to people or get license taken away ..umm when it is 87% effective against death and kills virus within houses keeping it from spreading ..hospital percentage down.. it’s about mo ey and depopulation. I’d join an ivermectin trial in a heartbeat if I get covid..but I probably wont beings I take ivermectin from other sources..lol